ABVC BioPharma, Inc. Repayments of Convertible Debt
ABVC BioPharma, Inc. (ABVC) reported Repayments of Convertible Debt of $277.28 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Cash Flow › Financing Activities
us-gaap:RepaymentsOfConvertibleDebt · last filed 2026-03-03
- ABVC BioPharma, Inc. repayments of convertible debt for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- ABVC BioPharma, Inc. repayments of convertible debt for the quarter ending 2024-12-31 was $147.89K.
- ABVC BioPharma, Inc. repayments of convertible debt for the quarter ending 2021-12-31 was $0.00.
- ABVC BioPharma, Inc. repayments of convertible debt for the quarter ending 2021-09-30 was $0.00.
- ABVC BioPharma, Inc. repayments of convertible debt for fiscal 2025 was $277.28K, a 15.21% decline from fiscal 2024.
- ABVC BioPharma, Inc. repayments of convertible debt for fiscal 2024 was $327.02K.
- ABVC BioPharma, Inc. repayments of convertible debt for fiscal 2021 was $306.84K.
| Period end | Repayments of Convertible Debt 3 month | Repayments of Convertible Debt 6 month | Repayments of Convertible Debt 9 month | Repayments of Convertible Debt 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-03 | $277.28K 10-K · filed 2026-03-03 | ||
| 2025-09-30 | $277.28K 10-Q/A · filed 2026-03-03 | |||
| 2024-12-31 | $147.89K derived: 10-K 12 month − 10-Q/A 9 month · filed 2026-03-03 | $327.02K 10-K · filed 2026-03-03 | ||
| 2024-09-30 | $179.13K 10-Q/A · filed 2026-03-03 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $56.84K derived: sum of 3 quarters · filed 2023-03-31 | $306.84K 10-K · filed 2023-03-31 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $56.84K derived: sum of 2 quarters · filed 2022-11-14 | $306.84K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $56.84K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $306.84K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $250.00K 10-Q · filed 2022-05-16 |